t
GSK plc held its 26th Annual General Meeting on 6 May 2026. All 25 resolutions, including the adoption of the 2025 Annual Report and re-election of directors, were passed by a poll. The total votes cast and votes withheld represented 76.59% of GSK's issued share capital as of 1 May 2026.
| Date | 6 May 2026 |
| Time | 18:22:16 |
| Category | AGMs and other meetings |
| ID | 3149D |
Issued: 6 May 2026, London UK
Results of 26th Annual General Meeting
 |
GSK plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm on Wednesday 6 May 2026 at the London Marriott Hotel Grosvenor Square, Grosvenor Square, London, W1K 6JP. Shareholders were able to join the meeting in person or virtually via the Lumi Global website and Zoom.
All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.
All 25 resolutions were passed and decided upon by a poll. The table below shows the results for each resolution. The full text of the resolutions is contained in the Notice of AGM published on 25 March 2026, which is available on GSK's website at www.gsk.com.
|
Resolution |
Total votes for(1)(2) |
% |
Total votes against(2) |
% |
Total votes cast |
% of Issued Share Capital voted(3) |
Votes withheld(4) |
|
|
1 |
Receive and adopt the 2025 Annual Report |
3,073,839,952 |
99.25 |
23,182,191 |
0.75 |
3,097,022,143 |
76.38% |
8,652,004 |
|
2 |
Approve the Annual report on remuneration |
2,986,046,185 |
96.74 |
100,644,457 |
3.26 |
3,086,690,642 |
76.12% |
18,986,231 |
|
3 |
Approve the Remuneration policy |
3,066,582,993 |
98.96 |
32,182,945 |
1.04 |
3,098,765,938 |
76.42% |
6,914,570 |
|
4 |
Election of Luke Miels |
3,081,325,569 |
99.37 |
19,501,818 |
0.63 |
3,100,827,387 |
76.47% |
4,845,132 |
|
5 |
Re-election of Sir Jonathan Symonds |
3,079,744,123 |
99.32 |
21,127,306 |
0.68 |
3,100,871,429 |
76.47% |
4,793,341 |
|
6 |
Re-election of Julie Brown |
3,069,722,312 |
99.00 |
31,102,814 |
1.00 |
3,100,825,126 |
76.47% |
4,848,203 |
|
7 |
Re-election of Elizabeth McKee Anderson |
3,042,023,812 |
98.52 |
45,732,363 |
1.48 |
3,087,756,175 |
76.15% |
17,906,882 |
|
8 |
Re-election of Charles Bancroft |
3,070,002,110 |
99.43 |
17,646,639 |
0.57 |
3,087,648,749 |
76.15% |
18,018,954 |
|
9 |
Re-election of Dr Hal Barron |
3,080,985,163 |
99.37 |
19,595,495 |
0.63 |
3,100,580,658 |
76.47% |
5,088,510 |
|
10 |
Re-election of Dr Anne Beal |
3,048,091,490 |
98.71 |
39,715,257 |
1.29 |
3,087,806,747 |
76.15% |
17,858,160 |
|
11 |
Re-election of Wendy Becker |
3,031,625,476 |
98.18 |
56,091,438 |
1.82 |
3,087,716,914 |
76.15% |
17,946,122 |
|
12 |
Re-election of Dr Harry C Dietz |
3,094,560,703 |
99.80 |
6,160,152 |
0.20 |
3,100,720,855 |
76.47% |
4,943,572 |
|
13 |
Re-election of Dr Jeannie Lee |
3,095,593,233 |
99.84 |
5,084,831 |
0.16 |
3,100,678,064 |
76.47% |
4,985,598 |
|
14 |
Re-election of Dr Gavin Screaton |
3,095,403,626 |
99.83 |
5,240,337 |
0.17 |
3,100,643,963 |
76.47% |
5,019,966 |
|
15 |
Re-election of Dr Vishal Sikka |
3,095,036,695 |
99.82 |
5,513,088 |
0.18 |
3,100,549,783 |
76.47% |
5,111,280 |
|
16 |
Re-appointment of the auditor |
3,099,113,772 |
99.94 |
1,891,083 |
0.06 |
3,101,004,855 |
76.48% |
4,664,323 |
|
17 |
Remuneration of the auditor |
3,098,976,181 |
99.94 |
1,736,335 |
0.06 |
3,100,712,516 |
76.47% |
4,949,197 |
|
18 |
Authority for the company to make donations to political organisations and incur political expenditure |
3,039,847,574 |
98.91 |
33,534,985 |
1.09 |
3,073,382,559 |
75.80% |
32,288,122 |
|
19 |
Authority to allot shares |
2,999,108,776 |
96.74 |
100,960,760 |
3.26 |
3,100,069,536 |
76.45% |
5,592,295 |
|
20 |
Disapplication of pre-emption rights - general power(5) |
3,046,584,734 |
98.32 |
51,962,919 |
1.68 |
3,098,547,653 |
76.42% |
7,072,535 |
|
21 |
Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment(5) |
3,059,992,748 |
98.75 |
38,710,772 |
1.25 |
3,098,703,520 |
76.42% |
6,947,940 |
|
22 |
Authority for the company to purchase its own shares(5) |
3,093,867,095 |
99.82 |
5,669,416 |
0.18 |
3,099,536,511 |
76.44% |
6,127,609 |
|
23 |
Exemption from statement of senior statutory auditor's name |
3,079,861,236 |
99.81 |
5,739,421 |
0.19 |
3,085,600,657 |
76.10% |
20,038,163 |
|
24 |
Authority for reduced notice of a general meeting other than an AGM(5) |
2,911,856,203 |
93.98 |
186,503,587 |
6.02 |
3,098,359,790 |
76.41% |
7,285,017 |
|
25 |
Approve the amended Articles of Association(5) |
3,065,959,469 |
99.40 |
18,375,929 |
0.60 |
3,084,335,398 |
76.07% |
21,304,284 |
Notes:
(1) The "for" votes include those giving the Chair discretion.
(2) Votes "for" and "against" are expressed as a percentage of the total votes cast.
(3) The Company's issued share capital as at 1 May 2026 consisted of 4,054,826,603 shares of 31 ¼ pence each ('Ordinary Shares') excluding Ordinary Shares held in Treasury. Every shareholder has one vote for every
Ordinary Share held.
(4) A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
(5) Indicates Special Resolutions requiring a 75% majority of votes cast.
The following table provides further information on participation in the AGM:
|
|
GSK's 26th AGM (Hybrid meeting) (2026) |
GSK's 25th AGM (Hybrid meeting) (2025) |
|
Issued share capital (excluding Treasury Shares) |
4,054,826,603 |
4,109,037,095 |
|
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares) |
76.59% |
74.21% |
|
Total shareholder population |
55,305 |
57,405 |
|
Total number of proxies lodged |
2,475 |
2,617 |
|
Number of shareholders in attendance |
117 in person 17 participated virtually |
130 in person 25 participated virtually |
|
% of shareholders who lodged proxies |
4.48% |
4.56% |
The above poll results will shortly be available on the company's website at www.gsk.com.
In accordance with Listing Rule 6.4.2 of the Financial Conduct Authority's (FCA) Listing Rules, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the FCA and will, in due course, be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
V A Whyte
Company Secretary
6 May 2026
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG